XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental information (Tables)
 6 Months Ended
Feb. 29, 2024
Supplemental Cash Flow Elements [Abstract]  
Schedule of Depreciation and Amortization Expense
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
Three months endedSix months ended
February 29, 2024February 28, 2023February 29, 2024February 28, 2023
Depreciation expense$374 $361 $751 $697 
Intangible assets amortization239 199 478 357 
Total depreciation and amortization expense$613 $559 $1,230 $1,055 
Restrictions on Cash and Cash Equivalents The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of February 29, 2024 and August 31, 2023, respectively (in millions):
February 29, 2024August 31, 2023
Cash and cash equivalents$668 $739 
Cash and cash equivalents - assets held for sale (included in other current assets)— 24 
Restricted cash - (included in other current and non-current assets)47 93 
Cash, cash equivalents and restricted cash$715 $856 
Schedule of Redeemable Noncontrolling Interest
The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions):
Three months endedSix months ended
February 29, 2024February 28, 2023February 29, 2024February 28, 2023
Opening balance$169 $157 $167 $1,042 
Net loss attributable to Redeemable non-controlling interests2 (1)2 (24)
Redemption price adjustments and other 1
2 3 4 454 
Reclassifications to Accrued expenses and other liabilities 2
— — — (1,314)
Ending balance$172 $158 $172 $158 

1.Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended
November 30, 2022, Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value as the Company announced the acceleration of its plans for their full ownership.
2.Represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities within the Consolidated Condensed Balance Sheets, resulting from the Company's full acquisition of Shields and CareCentrix.
Schedule of Dividends Payable
Cash dividends per common share declared were as follows:

Quarter ended20242023
November$0.4800 $0.4800 
February$0.2500 $0.4800 
Total$0.7300 $0.9600